Julie Lorent
Impact in
Papers in
- Oncology 5
- Cancer Cells and Metastasis 2
-
- RNA Research and Splicing 2
- RNA and protein synthesis mechanisms 2
- RNA modifications and cancer 2
- Co-authors
- Michael Leahy (1 shared paper)J. Martijn Kerst (1 shared paper)Gedske Daugaard (1 shared paper)Pablo Maroto (1 shared paper)Sandrine Marréaud (1 shared paper)Iwona Skoneczna (1 shared paper)Maria De Santis (1 shared paper)Sandra Collette (1 shared paper)
- Journals
- Nucleic Acids Research (2 papers)Molecular Oncology (1 paper)Statistical Applications in Genetics and Molecular Biology (1 paper)British Journal of Cancer (1 paper)Journal of Clinical Oncology (1 paper)
- Partner nations
- SwedenCanadaUnited States
In The Last Decade
Julie Lorent
15 papers receiving 960 citations
Hit Papers
Peers
Comparison fields: 5 of 87
- Oncology 443
- Surgery 502
- Immunology 183
- Cancer Research 99
- Urology 32
Countries citing papers authored by Julie Lorent
This map shows the geographic impact of Julie Lorent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Lorent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Lorent more than expected).
Fields of papers citing papers by Julie Lorent
This network shows the impact of papers produced by Julie Lorent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Lorent. The network helps show where Julie Lorent may publish in the future.
Co-authors
The 25 scholars most cited alongside Julie Lorent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 Hit paper breakdown → | 2011 | 523 |
| 2 | 2016 | 121 | |
| 3 | 2019 | 49 | |
| 4 | 2017 | 46 | |
| 5 | 2015 | 42 | |
| 6 | 2018 | 37 | |
| 7 | 2011 | 29 | |
| 8 | 2014 | 22 | |
| 9 | 2018 | 22 | |
| 10 | 2020 | 21 | |
| 11 | 2018 | 21 | |
| 12 | 2017 | 18 | |
| 13 | 2015 | 16 | |
| 14 | 2023 | 5 | |
| 15 | 2024 | 1 |
About Julie Lorent
Julie Lorent is a scholar working on Oncology, Molecular Biology, Cancer Research, Epidemiology and Immunology, having authored 15 papers that have together received 973 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (3 papers), Cancer Cells and Metastasis (2 papers), RNA Research and Splicing (2 papers), Cancer Genomics and Diagnostics (2 papers), RNA and protein synthesis mechanisms (2 papers), RNA modifications and cancer (2 papers), Mast cells and histamine (1 paper) and Dermatologic Treatments and Research (1 paper). The work is most often cited by research in Oncology (443 citations), Surgery (502 citations), Immunology (183 citations), Cancer Research (99 citations) and Urology (32 citations). Julie Lorent has collaborated with scholars based in Sweden, Canada and United States. Frequent co-authors include Michael Leahy, J. Martijn Kerst, Gedske Daugaard, Pablo Maroto, Sandrine Marréaud, Iwona Skoneczna, Maria De Santis, Sandra Collette, Thierry Gil and Richard Sylvester. Their work appears in journals such as Nucleic Acids Research, Molecular Oncology, Statistical Applications in Genetics and Molecular Biology, British Journal of Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.